One of the world's leading pharmacogenomics researchers explains how your genes affect drug response in practical terms — covering CYP enzymes, why the same medication dose works differently in different people, and where personalized medicine is heading.
McLeod, one of the founding figures of clinical pharmacogenomics, explains — in plain language — how CYP2D6, CYP2C19, TPMT, DPYD, and other drug-metabolism genes shape response to common medications, from antidepressants to codeine to chemotherapy. Real patient cases illustrate every concept.
McLeod chaired the Clinical Pharmacogenetics Implementation Consortium (CPIC) and helped write the guidelines that hospitals now use to interpret PGx tests — this is the field explained by one of its architects.
These peer-reviewed studies connect to the core ideas in this book. Each result has been scored for reliability.
Covers the broader context of psychiatric medication — how drugs are approved, why responses vary between individuals, and what the research actually shows about long-term use. Relevant for anyone researching CYP2D6, CYP2C19, and psychiatric medication response genetics.
A Harvard psychiatrist's practical guide to tapering and discontinuing antidepressants. Written before pharmacogenomics was widely accessible but remains the most practical clinical reference for medication discontinuation — relevant alongside CYP2D6 and SLC6A4 research.